GLP-1 Medications: Metabolic Breakthrough — or Are We Skipping a Step?

A reflection on long-term physiology, Australian data, and the foundations we can’t afford to ignore

Few medications in recent history have generated as much attention as Ozempic, Wegovy and Mounjaro.

In Australia, where more than 1.3 million people live with diagnosed diabetes — around 85–90% Type 2 (AIHW, 2023) — and almost two-thirds of adults are overweight or obese (ABS, 2022), it’s not surprising that a medication producing significant weight loss and improved glycaemic control has been welcomed.

For many patients, GLP-1 receptor agonists have been transformative, and that deserves acknowledgement.

But it’s also relevant to ask what those outcomes may mean long term.

What the Evidence Shows

GLP-1 receptor agonists mimic the action of the naturally occurring hormone glucagon-like peptide-1, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying and increasing satiety.

Large trials such as:

  • SUSTAIN and STEP (semaglutide)
  • SURPASS (tirzepatide)

have demonstrated:

  • Significant HbA1c reduction
  • Average weight loss of 10–20% depending on dose
  • Reduction in major adverse cardiovascular events in high-risk individuals (Marso et al., NEJM, 2016; Wilding et al., NEJM, 2021)
  • A reduction in death from chronic kidney disease compared to other medications (Chen J, Wu C, Jenq C, et al. JAMA Netw Open. 2022;5(3):e221169. doi:10.1001/jamanetworkopen.2022.1169)

From a cardiometabolic risk perspective, that’s not trivial.

However, there are several shortcomings with the work done so far:

1.     None of these trials were long enough to assess 20- or 30-year endocrine adaptation.

2.     They cannot determine whether the underlying metabolic drivers of Type 2 diabetes were resolved. The studies only measure outcomes like blood sugar levels or weight loss, which could be pharmacologically driven in the short term without resulting in a return to a healthy state.

3.     All the trials will under-report negative effects and over report success because the other factors such as diet and exercise were tightly controlled in the trials limiting malnutrition and improving outcomes.

4.     Real world data shows much lower weight loss than clinical trials.

5.     The head-to-head trials that have been done show that GLP-1Ras are not more effective than diet and exercise (though they do increase weight loss in combination).

The difference between tightly controlled trials and prescription use of these drugs is significant.

Are We Repairing Physiology — or Overriding It?

GLP-1 receptor agonists stimulate a receptor.
They do not rebuild metabolic capacity.

Type 2 diabetes is strongly associated with:

  • Chronic insulin resistance
  • Low skeletal muscle mass
  • Visceral adiposity
  • Gut microbiome dysbiosis
  • Chronic low-grade inflammation

Australian dietary data consistently shows fibre intake remains well below recommended levels. Most adults do not reach the suggested 25–30g per day (ABS Nutrition Survey).

Yet fibre intake is directly linked to:

  • Improved insulin sensitivity
  • Increased short-chain fatty acid production
  • Endogenous GLP-1 secretion
  • Reduced systemic inflammation

Research in Nature Reviews Endocrinology and Cell Metabolism has demonstrated that microbial fermentation products such as butyrate and propionate stimulate natural GLP-1 release via enteroendocrine signalling pathways.

In other words, the body already possesses a GLP-1 system — one that is diet-responsive.

The question becomes:

Are we supporting that system — or bypassing it?

The Rebound Effect

One of the most consistent findings in follow-up studies is that when GLP-1 therapy is discontinued, weight regain is common and glycaemic control often deteriorates (Rubino et al., Diabetes Care, 2021).

This does not prove that natural GLP-1 production is damaged, however it has been shown in many systems that the feedback from mimic drugs results in the “switching off” of natural production, particularly when the drug has a significantly longer life than the natural molecule. If receptors are continually stimulated the body tends to reduce how many are there – this is called habituation and occurs with most pharmaceuticals.

There is currently no robust evidence of permanent suppression of endogenous GLP-1 secretion, however early stage studies have shown short term suppression.

However, chronic receptor stimulation in any endocrine pathway can lead to adaptive shifts. Whether those adaptations are clinically significant over decades remains unknown.

Given that these medications may be prescribed indefinitely, long-term metabolic resilience should remain part of the discussion.

“Mild to Moderate” — Through Whose Lens?

In regulatory language, nausea, vomiting, constipation, diarrhoea and fatigue are often categorised as “mild to moderate.”

Medically, that classification is accurate — it refers to severity thresholds, not triviality.

Yet from a patient’s lived experience, persistent gastrointestinal distress or profound appetite suppression can affect quality of life and nutritional adequacy.

There are also documented increases in:

  • Gallbladder disease
  • Risk of pancreatitis (rare but serious)
  • Lean muscle mass loss during rapid weight reduction (more significant than other weight loss methods)

Lean mass loss is particularly relevant in older adults, where sarcopenia increases frailty risk — a growing concern in Australia’s ageing population.

Transparency is not anti-medicine. It is good medicine.

The Bigger Public Health Question

Australia spends over $3 billion annually on diabetes-related health costs (AIHW).

If GLP-1 therapies reduce complications and hospital admissions, that may represent important economic value.

But if they are used without addressing:

  • Muscle conditioning
  • Dietary quality
  • Fibre sufficiency
  • Sleep and stress regulation
  • Inflammatory drivers

then we risk substituting pharmacology for physiology.

Medications can reduce risk.
They cannot replace metabolic education.

A Both - And Model

It is possible — and sensible — to hold two truths at once:

GLP-1 receptor agonists are powerful, evidence-based tools.

And sustainable metabolic health requires foundational repair.

For some patients, medication may act as a circuit-breaker — reducing appetite, improving glucose control and creating space for behavioural change.

For others, without deeper intervention, it may become a long-term dependency.

The distinction lies not in the drug itself, but in the strategy surrounding its use.

The Hard but Necessary Question

Are we building metabolic resilience — or outsourcing it?

If we combine appropriate pharmacotherapy with:

  • Restoration of dietary fibre intake
  • Support of gut microbiome diversity
  • Progressive resistance training
  • Anti-inflammatory nutritional patterns
  • Patient education and ultimately
  • A more health-oriented food system.

then we are using innovation wisely.

If we rely solely on receptor activation while underlying dysfunction persists, we may simply be postponing a more complex problem.

Where Responsible Medicine Sits

This is not a call to reject GLP-1 therapies.

Nor is it an endorsement of bypassing lifestyle intervention.

It is a call for integration.

In an era of escalating metabolic disease, the real breakthrough may not be pharmacological alone — but a system that restores the body’s own regulatory intelligence while using modern medicine judiciously.

Innovation is welcome.

Physiology still matters.

In Closing: A Food-as-Medicine Perspective

As we navigate a rapidly evolving therapeutic landscape, one principle remains constant: the human body is not a collection of isolated receptors. It’s an integrated biological system shaped daily by food, movement, sleep, stress and microbial ecology.

GLP-1 receptor agonists represent a significant pharmacological advancement. For some individuals, they may provide a powerful circuit-breaker — reducing metabolic risk and creating space for change.

But long-term resilience rarely arises from receptor activation alone.

The same GLP-1 pathways targeted by medication are also influenced by dietary fibre, gut microbial fermentation, muscle activity and inflammatory load. When we nourish those pathways through whole-food strategies, adequate fibre intake and metabolic conditioning, we support the body’s intrinsic regulatory intelligence.

This is not an argument against innovation.

It is an argument for integration.

Medication can be a tool.
Food can be signalling.
Muscle can be medicine.
Education can be protection.

The future of metabolic health in Australia may not lie in choosing between pharmacology and physiology — but in ensuring they work together, with long-term resilience as the goal.

References

Australian Bureau of Statistics (ABS). (2022). National Health Survey 2020–21: Overweight and obesity. Canberra: ABS.

Australian Bureau of Statistics (ABS). (2014). Australian Health Survey: Nutrition First Results – Foods and Nutrients. Canberra: ABS.

Australian Institute of Health and Welfare (AIHW). (2023). Diabetes: Australian facts. Canberra: AIHW.

Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375, 1834–1844.

Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384, 989–1002.

Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. Diabetes Care, 44(3), 672–679.

Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130.

Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fibre to host physiology: short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332–1345.

Chambers, E. S., Preston, T., Frost, G., & Morrison, D. J. (2018). Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Current Nutrition Reports, 7, 198–206.

Back to Blog